Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis
- Status
- CompletedResults posted
- Why it is watched
- non-weight indication: osteoarthritis
- Who it enrolls
- healthy volunteers accepted; BMI ≥30 required; conditions: Obesity
- Interventions
- semaglutide 2.4 mg; semaglutide 2.4 mg (placebo)
- Conditions
- Obesity
- Phase and size
- Phase 3 · 407 participants
- Dates
- Start 2021-10-01
Primary completion 2023-07-24 - Sponsor
- Novo Nordisk A/S (Industry)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Percentage Change in Body WeightBaseline (week 0), end of treatment (week 68)
- Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain ScoreBaseline (week 0), end of treatment (week 68)
Published results in the collection
- Once-Weekly Semaglutide in Persons with Obesity and Knee OsteoarthritisRandomized trial · 2024 · Study tier 2 · Different population · Benefit · Industry funded
02Eligibility
Who can take part
Inclusion Criteria: * Male or female, age above or equal to 18 years at the time of signing informed consent * Body Mass Index (BMI) equal to or greater than 30.0 kg/m\^2 * Clinical diagnosis of knee OA (American College of Rheumatology (ACR) criteria) with moderate radiographic changes (Kellgren-Lawrence (KL) grades 2 or 3 as per central reading) in target knee. Target knee joint is defined as most symptomatic knee at screening. If pain in knees are equal target knee joint will be in the most dominant leg. * Pain due to knee OA Exclusion Criteria: * Joint replacement in target knee * Arthroscopy or injections into target knee within last 3 months prior to enrolment * Any other joint disease in the target knee
03Change log
Registry changes
No changes recorded since the trial was added.